1998
Vaccination against Lyme Disease with Recombinant Borrelia burgdorferi Outer-Surface Lipoprotein A with Adjuvant
Steere A, Sikand V, Meurice F, Parenti D, Fikrig E, Schoen R, Nowakowski J, Schmid C, Laukamp S, Buscarino C, Krause D. Vaccination against Lyme Disease with Recombinant Borrelia burgdorferi Outer-Surface Lipoprotein A with Adjuvant. New England Journal Of Medicine 1998, 339: 209-215. PMID: 9673298, DOI: 10.1056/nejm199807233390401.Peer-Reviewed Original ResearchConceptsLyme diseaseSerologic testingVaccine efficacyAsymptomatic infectionLipoprotein AInjections of vaccineOuter surface lipoprotein AB. burgdorferi infectionFirst yearPlacebo recipientsPlacebo groupVaccine groupVaccine recipientsStudy entryRandomized trialsSystemic reactionsThird injectionBurgdorferi infectionEffective vaccineSkin lesionsReaction testingVaccineDefinite casesDiseaseInfection
1987
Epidemiology of American Cutaneous Leishmaniasis Due to Leishmania braziliensis brasiliensis
Jones T, Johnson W, Barretto A, Lago E, Badaro R, Cerf B, Reed S, Netto E, Tada M, Franca F, Wiese K, Golightly L, Fikrig E, Costa J, Cuba C, Marsden P. Epidemiology of American Cutaneous Leishmaniasis Due to Leishmania braziliensis brasiliensis. The Journal Of Infectious Diseases 1987, 156: 73-83. PMID: 3598227, DOI: 10.1093/infdis/156.1.73.Peer-Reviewed Original ResearchConceptsPrimary lesionMucosal diseaseCutaneous leishmaniasisFive-year prospective studyLeishmania braziliensis braziliensisYears of ageAmerican cutaneous leishmaniasisAntimony therapyAnnual incidenceSkin testingProspective studyRecent lesionsSkin testSkin lesionsEndemic areasPatientsLesionsDiseaseMost diseasesLeishmaniasisYearsTherapyEpidemiologyPrevalenceIncidence